Created by three CNRS researchers, the start-up is developing a treatment against glaucoma, a disease of the retina of the eye, causing degeneration of the optic nerve leading to total loss of vision in the affected patient.
“Our research is based on the discovery of one of our associates, Krys Rogowski, who in 2017 identified an enzyme acting in the process of neurodegeneration of cells, summarizes Siem Van Der Laan, CEO of MT-Act. to this, we incorporated a project maturation program at SATT AxLR, in order to work on the creation of a treatment against degeneration, which led to the creation of the company. "
Affecting 120 million people worldwide, glaucoma represents a market of € 5 billion for its medication. Great commercial prospects for MT-Act, the treatment of which could be adapted to the entire central nervous system, and to Alzheimer's disease. However, there is still a long way to go for the start-up, which does not hope to put its treatment on the market before 2030.
